SCHEMBL24314307

SCHEMBL24314307

O=C(O)c1ccc2cc(C(=O)N[S+]([O-])c3ccccc3-c3ccccc3)oc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
NPC1 O15118 4/20 0.45
TP53 P04637 3/20 0.45
HDAC6 Q9UBN7 3/20 0.43
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
PKM P14618 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
GALK1 P51570 1/20 0.38
MIF P14174 2/20 0.38
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
PGR P06401 1/20 0.36
TSHR P16473 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24313744 0.90 HDAC6 (0.40) RAB9ASMN1; SMN2NPC1TP53HDAC6
SCHEMBL24313631 0.90 HDAC6 (0.40) RAB9ASMN1; SMN2NPC1TP53HDAC6
SCHEMBL22601061 0.88 CHRNA7 (0.40) RAB9ASMN1; SMN2NPC1TP53HDAC6
SCHEMBL22601033 0.88 NPC1 (0.51) RAB9ASMN1; SMN2NPC1TP53PKM
SCHEMBL24313789 0.87 NPC1 (0.43) RAB9ASMN1; SMN2NPC1TP53PKM
SCHEMBL22600839 0.87 RAB9A (0.41) RAB9ASMN1; SMN2NPC1TP53HDAC6
SCHEMBL26008098 0.85 SLC16A3 (0.42) RAB9ASMN1; SMN2NPC1TP53PKM
SCHEMBL22601146 0.85 NPC1 (0.39) RAB9ASMN1; SMN2NPC1TP53PKM
SCHEMBL24313952 0.84 NPC1 (0.43) RAB9ASMN1; SMN2NPC1TP53PKM
SCHEMBL24313970 0.84 ALDH1A1 (0.40) RAB9ASMN1; SMN2NPC1TP53HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed